Pharmaceutical Research And Manufacturers Of America
lobbying client · lobbying firm
Pharmaceutical Research And Manufacturers Of America's federal footprint — reported lobbying spend and, where matched, federal money received. Figures are as reported to the U.S. Senate (LDA) and USAspending.
Reported country: 🇺🇸 United States
Lobbying over time
| FY | Lobbying spend (as client) | Lobbying billed / handled (as firm) |
|---|---|---|
| 2022 | $33,130,000 | $28,290,000 |
| 2023 | $30,835,000 | $27,090,000 |
| 2024 | $35,032,500 | $31,000,000 |
| 2025 | $42,200,000 | $37,900,000 |
| 2026 | $45,000 | — |
Two figures: what Pharmaceutical Research And Manufacturers Of America reported spending on its own lobbying (as a client) and what it billed or handled for the clients it represents (as a firm — revenue, not its own spend). For a self-filer these overlap.
Firms hired
- Akin Gump Strauss Hauer & Feld $2,370,000 · 16 filings
- Miller Strategies, LLC $1,030,000 · 16 filings
- East End Group, LLC $1,020,000 · 18 filings
- Todd Strategy Group $1,020,000 · 17 filings
- W Strategies, LLC $960,000 · 16 filings
- Crossroads Strategies, LLC $930,000 · 16 filings
- The Mcmanus Group $920,000 · 16 filings
- Bgr Government Affairs $920,000 · 16 filings
- Empire Consulting Group $800,000 · 16 filings
- Lesic And Camper Communications $800,000 · 16 filings
Registrants that filed lobbying on behalf of Pharmaceutical Research And Manufacturers Of America.
Clients represented
Self-filed — Pharmaceutical Research And Manufacturers Of America registers and lobbies on its own behalf, with no separate outside clients.
Issues
| Issue area | Lobbied | Worked |
|---|---|---|
| Health Issues | 214 | 16 |
| Medicare/Medicaid | 128 | 16 |
| Pharmacy | 99 | — |
| Copyright/Patent/Trademark | 75 | 16 |
| Trade (domestic/foreign) | 71 | 16 |
| Budget/Appropriations | 56 | 16 |
| Consumer Issues/Safety/Products | 11 | — |
| Taxation/Internal Revenue Code | 11 | — |
| Defense | 5 | — |
| Insurance | 1 | — |
Issue areas across Pharmaceutical Research And Manufacturers Of America's filings, by activity count — as the client (Lobbied) and as the registrant/firm (Worked). Linked areas open the CivicGate issue page.
What they lobbied on
Reported activity from Senate LDA
-
FY2026 Budget/Appropriations as client
Fiscal Year 2027 Appropriations bills
-
FY2025 Health Issues as client
Issues relating to drug pricing proposals including implementation of the Inflation Reduction Act (P.L. 117-169); Rx oversight issues; PBM oversight issues; Issues related to budget reconciliation; Issues related to Most Favored Nation proposals; Issues related to the FTC.
-
FY2025 Trade (domestic/foreign) as client
Issues related to IP protection; Market access issues related to PhRMA 232.
-
FY2025 Copyright/Patent/Trademark as client
Issues related to patent reform legislation; H.R. 3160/S. 1553 - PREVAIL Act
-
FY2025 Health Issues as client
340B and drug pricing
-
FY2025 Budget/Appropriations self-filed
H.R. 1: One Big Beautiful Bill Act H.R. 3944: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026 H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 4213: Department of Homeland Security Appropriations Act, 2026 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. __: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. __: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. __: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 S. __: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026
H.R. 1 H.R. 3944 H.R. 4121 H.Res. 566 H.Con.Res. 14 H.R. 4213 S. 2256
-
FY2025 Copyright/Patent/Trademark self-filed
S. 43: Skinny Labels, Big Savings Act S. 708: RESTORE Patent Rights Act of 2025 S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 1574: RESTORE Patent Rights Act of 2025 H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues Patent use codes policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues
S. 43 S. 708 S. 1040 S. 1041 S. 1095 S. 1096 S. 1097 S. 1546 S. 1553 H.R. 890 H.R. 1574 H.R. 3152 H.R. 3160 H.R. 3269
-
FY2025 Health Issues self-filed
S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 S. 1302: Increasing Transparency in Generic Drug Applications Act S. 1414: Expedited Acccess to Biosimilars Act S. 1784: MAPS Act S. 2780: Medication Affordability and Patent Integrity Act S. 1954: Biosimilar Red Tape Elimination Act H.R. 1: One Big Beautiful Bill Act H.R. 946: Orphan Cures Act H.R. 1262: Give Kids a Chance Act of 2025 H.R. 1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 H.R. 2214: DRUG Act H.R. 4132: Prescription Information Modernization Act of 2025 H.R. 8574: 340B ACCESS Act Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Drug importation policy issues Accelerated approval policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Compounding policy issues Antimicrobial resistance (AMR) policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First
S. 355 S. 652 S. 832 S. 891 S. 932 S. 1302 S. 1414 S. 1784 S. 2780 S. 1954 H.R. 1 H.R. 946 H.R. 1262 H.R. 1492 H.R. 2214 H.R. 4132 H.R. 8574
Show 52 more activities
-
FY2025 Medicare/Medicaid self-filed
H.R. 1: One Big Beautiful Bill Act Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Insulin policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues Medicaid waiver policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues
-
FY2025 Trade (domestic/foreign) self-filed
Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues
-
FY2025 Pharmacy as client
Advise and advocate on clients behalf regarding ongoing public policy concerns impacting the innovative biopharmaceutical industry in Congress and throughout the Administration.
-
FY2025 Copyright/Patent/Trademark as client
Patent rights. Merchant rights.
-
FY2025 Pharmacy as client
Issues related to drug pricing. Issues realted to anti-competitive tactics in the pharmaceutical marketplace. S.1040 - Drug Competition Enhancement Act.
-
FY2025 Health Issues as client
Issues related to drug pricing proposals; Issues related to Rx oversight; Issues related to PBM oversight; Issues related to budget reconciliation; Issues related to Most Favored Nation proposals.
-
FY2025 Trade (domestic/foreign) as client
Issues related to IP protection; Issues related to market access; Issues related to PhRMA 232.
-
FY2025 Copyright/Patent/Trademark as client
Issues related to patent reform legislation; Issues related to H.R. 3160/S. 1553 - PREVAIL Act.
-
FY2025 Pharmacy as client
Issues related to prescription drug value, including H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; and implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including H.R. 2882, FY2024 Further Consolidated Appropriations Act. Issues related to the 340B program.
-
FY2025 Copyright/Patent/Trademark as client
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act.
-
FY2025 Trade (domestic/foreign) as client
Issues related to tariff and trade policy.
-
FY2025 Budget/Appropriations as client
Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7.
-
FY2025 Pharmacy as client
Pharmacy Benefit Manager (PBM) issues and reform. 340B. IRA implementation. H.R.1492: Ensuring Pathways to Innovative Cures (EPIC) Act. Drug pricing. International reference pricing. H.R.5378 - Lower Costs, More Transparency Act. H.R.5376 - Share the Savings with Seniors Act. H.R.6283/S.1542 - DRUG Act. H.R.830 - HELP Copays Act.
-
FY2025 Health Issues as client
General health care issues.
-
FY2025 Medicare/Medicaid as client
Public Law 119-21: One Big Beautiful Bill Act. Implementation of H.R.5376 Inflation Reduction Act. PBM reform legislation. Issues around drug pricing.
-
FY2025 Health Issues as client
H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act
-
FY2025 Health Issues as client
Promoting pharmaceutical research and development and ensuring access to medicines.
-
FY2025 Pharmacy as client
Advise and advocate on clients behalf regarding ongoing public policy concerns impacting the innovative biopharmaceutical industry in Congress and throughout the Administration.
-
FY2025 Health Issues as client
Promoting pharmaceutical research and development and ensuring access to medicines. Color of Gastrointestinal Illnesses.
-
FY2025 Health Issues as client
Issues relating to drug pricing proposals including implementation of the Inflation Reduction Act (P.L. 117-169); Rx oversight issues; PBM oversight issues.
-
FY2025 Trade (domestic/foreign) as client
Issues related to Section 301 tariffs; Issues related to IP protection; Market access issues.
-
FY2025 Copyright/Patent/Trademark as client
Issues related to patent reform legislation; H.R. 4370/S. 2220 - The PREVAIL Act (118th Congress).
-
FY2025 Health Issues as client
General representation. Regulations and legislation relating to PBMs and drug pricing. Issues related to the 340B drug discount program
-
FY2025 Health Issues as client
Promoting pharmaceutical research and development and ensuring access to medicines. Color of Gastrointestinal Illnesses.
-
FY2025 Health Issues as client
Healthcare
-
FY2025 Medicare/Medicaid as client
Part D changes. Prescription drug payment reform. 340B issues. Onshoring. S.864 - HELP Copays Act. General Medicare and Medicaid Issues.
-
FY2025 Pharmacy as client
Drug Pricing and Access. Pharmaceutical Supply Chain. Pharmacy Benefit Managers.
-
FY2025 Medicare/Medicaid as client
H.R.1 - One Big Beautiful Bill Act. Implementation of H.R.5376 Inflation Reduction Act. H.R.1492 - EPIC Act.
-
FY2025 Medicare/Medicaid as client
Medicare and healthcare policy issues as they relate to drug pricing, CMMI, and Medicare Part D; including rebate system reforms
-
FY2025 Medicare/Medicaid as client
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 839, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model
-
FY2025 Health Issues as client
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
-
FY2025 Health Issues as client
Healthcare
-
FY2025 Pharmacy as client
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
-
FY2025 Copyright/Patent/Trademark as client
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act.
-
FY2025 Trade (domestic/foreign) as client
Issues related to tariff and trade policy.
-
FY2025 Health Issues as client
Healthcare
-
FY2025 Health Issues as client
General representation. Regulations and legislation relating to PBMs and drug pricing. Issues related to the 340B drug discount program
-
FY2025 Budget/Appropriations as client
Fiscal Year 2025 Appropriations bills
-
FY2025 Pharmacy as client
Advise and advocate on clients behalf regarding ongoing public policy concerns impacting the innovative biopharmaceutical industry in Congress and throughout the Administration.
-
FY2025 Pharmacy as client
Pharmacy Benefit Manager (PBM) issues and reform. 340B. IRA implementation. H.R.1492: Ensuring Pathways to Innovative Cures (EPIC) Act. Drug pricing. Most-Favored Nation (MFN) International reference pricing. H.R.5378 - Lower Costs, More Transparency Act. H.R.5376 - Share the Savings with Seniors Act. H.R.6283/S.1542 - DRUG Act. H.R.830 - HELP Copays Act.
-
FY2025 Health Issues as client
General health care issues.
-
FY2025 Medicare/Medicaid as client
Part D changes. Prescription drug payment reform. 340B issues. Onshoring. S.864 - HELP Copays Act. General Medicare and Medicaid Issues.
-
FY2025 Pharmacy as client
Drug Pricing and Access. Pharmaceutical Supply Chain. Pharmacy Benefit Managers.
-
FY2025 Pharmacy as client
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
-
FY2025 Health Issues as client
S. 832, EPIC Act of 2025.
-
FY2025 Medicare/Medicaid as client
Medicare policies.
-
FY2025 Budget/Appropriations as client
S. Con. Res. 7, Budget Resolution for FY2025, provisions impacting pharmaceuticals. H. Con. Res. 14, Budget Resolution for FY2025, provisions impacting pharmaceuticals.
-
FY2025 Defense as client
National security issues related to pharmaceutical industry, including supply chain.
-
FY2025 Trade (domestic/foreign) as client
Trade policies and agreements, including IP protections, and administrative tariff actions.
-
FY2025 Budget/Appropriations self-filed
H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 3944: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026 H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 4213: Department of Homeland Security Appropriations Act, 2026 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 Government funding policy issues
H.R. 1 H.R. 3944 H.R. 4121 H.Res. 566 H.Con.Res. 14 H.R. 4213 S. 2256 H.R. 5304 S. 2587 H.R. 5342 S. 2354
-
FY2025 Copyright/Patent/Trademark self-filed
S. 43: Skinny Labels, Big Savings Act S. 708: RESTORE Patent Rights Act of 2025 S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 1574: RESTORE Patent Rights Act of 2025 H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues Patent use codes policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues
S. 43 S. 708 S. 1040 S. 1041 S. 1095 S. 1096 S. 1097 S. 1546 S. 1553 S. 2276 S. 2620 S. 2658 H.R. 890 H.R. 1574 H.R. 3152 H.R. 3160 H.R. 3269 H.R. 4570
-
FY2025 Trade (domestic/foreign) self-filed
S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues
The specific issues and bills Pharmaceutical Research And Manufacturers Of America reported lobbying on, newest first. Bill references that CivicGate tracks link to the bill; others are shown as reported.